Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

Concepto y epidemiología - Ponencias17. Gavlik A, Goldberg A, Tsaroucha MG, et al. Mycophenolatemofetil rescue therapy in liver transplant recipients. TransplantProc 1997; 29: 549-552.18. Schlitt HJ, Barkmann A, Bökeer KHW, Schmidt HHJ, EmmanouilidisN, Rosenau J, et al. Replacement of calcineurin inhibitorswith mycophenolate mofetil in liver-transplant patientswith renal dysfunction: a randomised controlled study.Lancet 2001; 357: 587-591.19. Neuberger J, Adams DH. What is the significance of acute liverallograft rejection. J Hepatol 1998; 29: 143-150.20. Berenguer M, Wright TL. Hepatitis C and liver transplantation.Gut 1999; 45: 159-163.21. Feray C, Samuel D, Gigou M, et al. An open trial of interferonalpha-recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology1995; 22: 1084-1088.22. Langrehr JM, Lohmann R, Raakow R, Jonas S, Klupp J, BechsteinWO, et al. Chronic rejection after orthotopic liver transplantationis increased under induction therapy with interleukin-2receptor antibody BT563. Transplant Proc 2001; 33:2290-2291.23. Rabbkin JM, de la Melena V, Orloff SL, Corless CL. RosenHR, Olyaei AJ. Late mortality after orthotopic liver transplantation.Am J Surg 2001; 181: 475-479.24. Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, DodsonSF, Marsh W, et al. Causes of retransplantation after primaryliver transplantation in 4000 consecutive patients: 2 to19 years follow-up. Transpl Proc 2001; 33: 1486-1487.39